We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LIN:NASDAQLinde plc Analysis

Data as of 2026-09-05 - not real-time

$477.57

Latest Price

3/10Risk

Risk Level: Low

Executive Summary

At $477.57, Linde plc shows no decisive moving-average alignment, leaving the trend neutral. The last 30 days have lost 6.8%. RSI sits at 38.5, which reads as approaching oversold, and MACD momentum is bullish. Recent trading has carved out support near $473.05 and resistance around $495.96.
The shares look fair at 30.9 times earnings, though no sector average was available for comparison. Sell-side targets cluster 14.0% above the current quote. Revenue is growing at 9.3% on a 20.4% profit margin. The 1.33% dividend yield looks covered by current payout levels.
The composite risk read is 3/10, putting it in low territory. With 30-day volatility of 22.5%, a beta of 0.08 and a maximum drawdown of 19.5%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 3 out of 10.

Top Market Events

Linde stock stayed close to $490 after a $4.Linde PLC LIN reports near double-digit growth in Q2 2026, driven by electronics and manufacturing recovery, while...Linde stock is trading close to recent highs after Q2 2026 results showed a profit margin above 20 p

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Trading below the 200-day average of 480.48
  • MACD momentum is positive
  • 30-day price change of -6.8%

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Trading below the 200-day average of 480.48
  • Analyst targets imply +14.0% versus the current price
  • MACD momentum is positive

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • Analyst targets imply +14.0% versus the current price
  • Profit margin of 20.4% is healthy
  • P/E ratio of 30.9

Key Metrics & Analysis

Financial Health

Revenue Growth9.30%
Profit Margin20.43%
P/E Ratio30.9
ROE18.40%
ROA7.16%
Debt/Equity68.95
P/B Ratio5.6
Op. Cash Flow$10.5B
Free Cash Flow$4.2B

Technical Analysis

TrendNeutral
RSI38.5
Support$473.05
Resistance$495.96
MA 20$484.62
MA 50$501.51
MA 200$480.48
MACDBullish
VolumeDecreasing
Fear & Greed Index95.48

Valuation

Fair Value$118.96
Target Price$544.54
Upside/Downside14.02%
GradeFair
TypeGrowth
Dividend Yield1.33%

Risk Assessment

Beta0.08
Volatility22.52%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.